Effects of Inhalable Microparticles of Seonpyejeongcheon-Tang in an Asthma Mouse Model - Effects of Microparticles of SJT -

  • Yang, Won-Kyung (Institute of Traditional Medicine and Bioscience, Daejeon University) ;
  • Lee, Chul-Hwa (Department of Respiratory System, Department of Internal Medicine, College of Korean Medicine, Daejeon University) ;
  • Kim, Min-Hee (Institute of Traditional Medicine and Bioscience, Daejeon University) ;
  • Kim, Seung-Hyeong (Institute of Traditional Medicine and Bioscience, Daejeon University) ;
  • Choi, Hae-Yoon (Department of Respiratory System, Department of Internal Medicine, College of Korean Medicine, Daegu Hanny University) ;
  • Yeo, Yoon (College of Pharmacy, Purdue University) ;
  • Park, Yang-Chun (Institute of Traditional Medicine and Bioscience, Daejeon University)
  • Received : 2016.08.19
  • Accepted : 2016.10.05
  • Published : 2016.12.31


Objectives: Allergic asthma generally presents with symptoms of wheezing, coughing, breathlessness, and airway inflammation. Seonpyejeongcheon-tang (SJT) consists of 12 herbs. It originated from Jeong-cheon-tang (JT), also known as Ding-chuan-tang, composed of 7 herbs, in She-sheng-zhong-miao-fang. This study aimed to evaluate the effects of local delivery of SJT via inhalable microparticles in an asthma mouse model. Methods: Microparticles containing SJT were produced by spray-drying with leucine as an excipient. SJT microparticles were evaluated with respect to their aerodynamic properties, in vitro cytotoxicity, in vivo toxicity, and therapeutic effects on ovalbumin (OVA)-induced asthma in comparison with orally-administered SJT. Results: SJT microparticles provided desirable aerodynamic properties (fine particle fraction of $48.9%{\pm}6.4%$ and mass median aerodynamic diameter of $3.7{\pm}0.3{\mu}m$). SJT microparticles did not show any cytotoxicity against RAW 264.7 macrophages at concentrations of 0.01 - 3 mg/mL. Inhaled SJT microparticles decreased the levels of IL-4, IL-5, IL-13, IL-17A, eotaxin and OVA-IgE in bronchoalveolar lavage fluid (BALF) in mice with OVA-induced asthma. These effects were verified by histological evaluation of the levels of infiltration of inflammatory cells and collagen, destructions of alveoli and bronchioles, and hyperplasia of goblet cells in lung tissues. The effects of SJT microparticles in the asthma model were equivalent to those of orally-administered SJT extract. Conclusion: This study suggests that SJT is a promising agent for inhalation therapy for patients with asthma.


Supported by : National Research Foundation of Korea (NRF)


  1. McKinnon M, Page K, Uings IJ, Banks M, Fattah D, Proudfoot AE, et al. An interleukin 5 mutant distinguishes between two functional responses in human eosinophils. J Exp Med. 1997;186(1):121-9.
  2. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79(12):3101-9.
  3. MacLean JA, Ownbey R, Luster AD. T cell-dependent regulation of eotaxin in antigen-induced pulmonary eosinophila. J Exp Med. 1996;184(4):1461-9.
  4. Yang Y, Tsifansky MD, Wu CJ, Yang HI, Schmidt G, Yeo Y. Inhalable antibiotic delivery using a dry powder co-delivering recombinant deoxyribonuclease and ciprofloxacin for treatment of cystic fibrosis. Pharm Res. 2010;27(1):151-60.
  5. Ben-Jebria A, Chen D, Eskew ML, Vanbever R, Langer R, Edwards DA. Large porous particles for sustained protection from carbachol-induced bronchoconstric-tion in guinea pigs. Pharm Res. 1999;16(4):555-61.
  6. Yang Y, Bajaj N, Xu P, Ohn K, Tsifansky MD, Yeo Y. Development of highly porous large PLGA micropar-ticles for pulmonary drug delivery. Biomaterials. 2009;30(10):1947-53.
  7. Kim SH, Kim BK, Lee YC. Antiasthmatic effects of hesperidin, a potential Th2 cytokine antagonist, in a mouse model of allergic asthma. Mediators Inflamm. 2011;2011:DOI: 10.1155/2011/485402.
  8. Duret C, Wauthoz N, Merlos R, Goole J, Maris C, Roland I, et al. In vitro and in vivo evaluation of a dry powder endotracheal insufflator device for use in dose-de-pendent preclinical studies in mice. Eur J Pharm Biop-harm. 2012;81(3):627-34.
  9. Liu C, Yang N, Song Y, Wang L, Zi J, Zhang S, et al. Gan-oderic acid C1 isolated from the anti-asthma formula, ASHMI suppresses TNF-alpha production by mouse macrophages and peripheral blood mononuclear cells from asthma patients. Int Immunopharmacol. 2015;27(2):224-31.
  10. Choi HJ, Bang NY, Song BW, Kim NJ, Rhyu BH. [Survey on the preference for the dosage forms of oriental herbal medicine]. J Kyung Hee Uni Med Cent. 2004;20(1):46-57. Korean.
  11. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacody-namics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28(5):1042-50.
  12. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol. 2008;8(3):183-92.
  13. Epstein MM. Targeting memory Th2 cells for the treatment of allergic asthma. Pharmacol Ther. 2006;109(1-2):107-36.
  14. Tomkinson A, Duez C, Cieslewicz G, Pratt JC, Joetham A, Shanafelt MC, et al. A murine IL-4 receptor antagonist that inhibits IL-4-and IL-13-induced responses prevents antigen-induced airway eosino-philia and airway hyperresponsiveness. J Immunol. 2001;166(9):5792-800.
  15. Walker C, Kaegi MK, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol. 1991;88(6):935-42.
  16. Caramori G, Pandit A, Papi A. Is there a difference between chronic airway inflammation in chronic severe asthma and chronic obstructive pulmonary disease?. Curr Opin Allergy Clin Immunol. 2005;5(1):77-83.
  17. Tillie-Leblond I, Gosset P, Tonnel AB. Inflammatory events in severe acute asthma. Allergy. 2005;60(1):23-9.
  18. Kao ST, Chang CH, Chen YS, Chiang SY, Lin JG. Effects of Ding-Chuan-Tang on bronchoconstriction and air-way leucocyte infiltration in sensitized guinea pigs. Im-munopharmacol Immunotoxicol. 2004;26(1):113-24.
  19. Chan CK, Kuo ML, Shen JJ, See LC, Chang HH, Huang JL. Ding Chuan Tang, a Chinese herb decoction, could improve airway hyper-responsiveness in stabilized asthmatic children: a randomized, double-blind clinical trial. Pediatr Allergy Immunol. 2006;17(5):316-22.
  20. Yoon JM, Park YC. [Protective effects of Seonpyejeong-cheon-tang on elastase-induced lung injury in mice]. Kor Journal Orient Int Med. 2010;31(1):84-101. Korean.
  21. Park YC. [A retrospective review of the effectiveness of Seonpyejeongcheon-tang on chronic cough]. Journal of Korean Medicine Institute of Daejeon University. 2012;20(2):111-6. Korean.
  22. KMFDS. [List of investigational new drug (2012.01.01-2012.12.31)]. Chungbuk: KMDFS; 2012.
  23. Park YC, Jin M, Kim SH, Kim MH, Namgung U, Yeo Y. Effects of inhalable microparticle of flower of Lonic-era japonica in a mouse model of COPD. J Ethnopharmacol. 2014;151(1):123-30.
  24. Ibrahim BM, Jun SW, Lee MY, Kang SH, Yeo Y. Development of inhalable dry powder formulation of basic fibroblast growth factor. Int J Pharm. 2010;385(1-2):66-72.
  25. Kay AB. Asthma and inflammation. J Allergy Clin Im-munol. 1991;87(5):893-910.
  26. Bousquet J, Jeffery PK, Busse WW, Johnson M, Vigno-la AM. Asthma. from bronchoconstriction to airways inflammation and remodeling. Am J Respir Crit Care Med. 2000;161(5):1720-45.
  27. Barrett NA, Austen KF. Innate cells and T helper 2 cell immunity in airway inflammation. Immunity. 2009;31(3):425-37.
  28. Bousquet J, Chanez P, Lacoste JY, Barneon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323(15):1033-9.

Cited by

  1. Identification of Epigenetic Mechanisms Involved in the Anti-Asthmatic Effects of Descurainia sophia Seed Extract Based on a Multi-Omics Approach vol.23, pp.11, 2018,